Scarica l'app Stockscreener
33.15
0.67%
0.22
Dopo l'orario di chiusura:
33.01
-0.14
-0.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$32.93
Aprire:
$32.92
Volume 24 ore:
2.30M
Relative Volume:
1.00
Capitalizzazione di mercato:
$9.47B
Reddito:
$2.08B
Utile/perdita netta:
$466.92M
Rapporto P/E:
21.25
EPS:
1.56
Flusso di cassa netto:
$404.94M
1 W Prestazione:
+2.38%
1M Prestazione:
-0.45%
6M Prestazione:
+41.36%
1 anno Prestazione:
+52.34%
Intervallo 1D:
$32.92
$33.65
Intervallo di 1 settimana:
$32.30
$33.65
Portata 52W:
$20.02
$37.59
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Confronta EXEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
33.15 | 9.47B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Smith Group Asset Management LLC Acquires New Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat
Exelixis (EXEL) to Release Quarterly Earnings on Tuesday - MarketBeat
Analysts Set Exelixis, Inc. (NASDAQ:EXEL) Target Price at $36.06 - MarketBeat
Exelixis announces results from expansion cohort of phase 1b/2 STELLAR-001 - MSN
Morgan Stanley lifts Exelixis stock rating to Overweight - MSN
Exelixis's SWOT analysis: cancer drug maker's stock faces patent cliff, pipeline promise - Investing.com
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
Exelixis patent discloses USP1 inhibitors for cancer - BioWorld Online
Exelixis's SWOT analysis: cabo strength drives stock amid IP challenges - MSN
Exelixis Sets Date for Major 2024 Performance Reveal: Key Details Inside - StockTitan
Is Exelixis a Biotech Stock Worth Adding to Your Portfolio? - Inkl
EXEL: Is Exelixis a Biotech Stock Worth Adding to Your Portfolio? - StockNews.com
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
Exelixis's SWOT analysis: cabo strength drives stock amid IP challenges By Investing.com - Investing.com Australia
Exelixis (NASDAQ:EXEL) Given Equal Weight Rating at Stephens - Defense World
Exelixis (NASDAQ:EXEL) Given New $43.00 Price Target at Truist Financial - Defense World
Exelixis (NASDAQ:EXEL) Rating Increased to Overweight at Morgan Stanley - Defense World
Exelixis (NASDAQ:EXEL) Given “Buy” Rating at HC Wainwright - Defense World
Exelixis downgraded by Oppenheimer to perform - MSN
Morgan Stanley lifts Exelixis stock rating to Overweight By Investing.com - Investing.com Canada
Morgan Stanley Upgrades Exelixis (EXEL) - MSN
Stifel maintains hold rating, $30 target on Exelixis stock - MSN
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform - Nasdaq
Exelixis (NASDAQ:EXEL) Price Target Raised to $43.00 - MarketBeat
Truist raises Exelixis stock target to $43 on Zanza optimism - MSN
Exelixis (NASDAQ:EXEL) Receives "Equal Weight" Rating from Stephens - MarketBeat
Truist raises Exelixis stock target to $43 on Zanza optimism By Investing.com - Investing.com UK
H.C. Wainwright maintains $40 target on Exelixis stock - Investing.com India
HC Wainwright Reaffirms "Buy" Rating for Exelixis (NASDAQ:EXEL) - MarketBeat
Exelixis stock holds Market Outperform rating, $41 target - MSN
This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Exelixis, Inc. (NASDAQ:EXEL) Stake Boosted by Nisa Investment Advisors LLC - Defense World
Park Avenue Securities LLC Purchases New Shares in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Nisa Investment Advisors LLC Increases Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
8,301 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by DGS Capital Management LLC - MarketBeat
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Exchange Traded Concepts LLC - MarketBeat
UMB Bank n.a. Purchases 553 Shares of Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis's SWOT analysis: cabozantinib strength, pipeline potential drive stock - MSN
Exelixis (NASDAQ:EXEL) Rating Lowered to “Market Perform” at Oppenheimer - Defense World
Exelixis (NASDAQ:EXEL) Stock Price Down 5.6%Here's Why - MarketBeat
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 - Business Wire
Exelixis falls after ASCO releases colorectal cancer data - MSN
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025 - Business Wire
Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33? - GuruFocus.com
Exelixis Faces Critical Crossroads: What’s Next? - Jomfruland.net
Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns - Yahoo Finance
Oppenheimer Downgrades Exelixis (NASDAQ:EXEL) to Market Perform - MarketBeat
Inspire Investing LLC Purchases 7,331 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Merit Financial Group LLC Invests $437,000 in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):